AQST News and Press, Aquestive Therapeutics Inc. From 10/11/22

FDA’s End-of-Phase 2 written response provides positive feedback related to Chemistry, Manufacturing, and Controls (CMC) to support future NDA filing Supports approach to characterizing Aquestive’s proprietary novel prodrug form of epinephrine API Confirms ...

Aquestive Therapeutics ( NASDAQ: AQST ) on Wednesday said it had entered into a licensing and supply agreement for its Libervant buccal film with healthcare company Pharmanovia. AQST's Libervant is a buccally, or inside of the cheek, administered film formulation of diazep...

WARREN, N.J., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Rob Byron / Shutterstock.com Aquestive Therapeutics (NASDAQ: AQST ) stock is taking off on Tuesday as investors react to positive clinical trial data from the pharmaceutical company. Aquestive Therap...

Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) gained ~20% pre-market Tuesday after the company announced that its AQST-109 epinephrine sublingual film compared favorably to other forms of epinephrine treatments, including EpiPen® autoinjector of Viatris ( VTRS ). ...

AQST-109 median time to maximum concentration ( Tmax ) of 12 minutes was faster than EpiPen ® Tmax of 22.5 minutes AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after admi...

WARREN, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the establishment...

Summary Shares have lost two-thirds of their value this year. AQST-109 looks like an appealing alternative to Epi-Pen with greater convenience and more consistent, rapid response. Libervant tentative approval by the FDA was disappointing as there's clearly a difference in food...

Summary After 8 months of waiting for an update from the FDA, the agency finally announced a tentative approval for Aquestive's Libervant. Unfortunately, the company cannot market the product. Aquestive Therapeutics recently reported their Q2 earnings, which revealed a beat on rev...

WARREN, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the managemen...